ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Hot Features

Registration Strip Icon for monitor Monitoree múltiples cotizaciones en tiempo real de los principales intercambios, como la Bolsa de Valores de Londres, NASDAQ, NYSE, AMEX, Bovespa y más.

HALO Halozyme Therapeutics Incorporated

38.11
-0.66 (-1.70%)
Última actualización: 14:57:22
Retrasado por 15 minutos
Nombre de la Acción Símbolo de la Acción Bolsa de Valores Tipo de Valor
Halozyme Therapeutics Incorporated HALO NASDAQ Acción Común
  Variación del Día (ptos.) Variación del Día (%) Último Precio Hora
-0.66 -1.70% 38.11 14:57:22
Precio de Apertura Precio Mínimo Precio Máximo Precio de cierre Precio Anterior
38.54 37.965 39.03 38.77
más cotizaciones de acciones »

Noticias Recientes

Fecha Hora Fuente Noticia
25/4/202415:45PRNUSMahesh Krishnan Elected to Halozyme's Board of Directors
23/4/202407:30PRNUSHalozyme to Report First Quarter 2024 Financial and..
04/3/202415:13EDGAR2Form PRE 14A - Other preliminary proxy statements
28/2/202417:49EDGAR2Form 4 - Statement of changes in beneficial ownership of..
28/2/202415:07EDGAR2Form 144 - Report of proposed sale of securities
27/2/202416:12EDGAR2Form 4 - Statement of changes in beneficial ownership of..
27/2/202416:05EDGAR2Form 4 - Statement of changes in beneficial ownership of..
27/2/202416:01EDGAR2Form 4 - Statement of changes in beneficial ownership of..
27/2/202415:08EDGAR2Form 144 - Report of proposed sale of securities
27/2/202407:30PRNUSHalozyme to Participate in Upcoming Investor Conferences
20/2/202417:59EDGAR2Form 4 - Statement of changes in beneficial ownership of..
20/2/202417:55EDGAR2Form 4 - Statement of changes in beneficial ownership of..
20/2/202417:53EDGAR2Form 4 - Statement of changes in beneficial ownership of..
20/2/202417:49EDGAR2Form 4 - Statement of changes in beneficial ownership of..
20/2/202415:07EDGAR2Form 10-K - Annual report [Section 13 and 15(d), not S-K..
20/2/202415:03EDGAR2Form 8-K - Current report
20/2/202415:01PRNUSHALOZYME REPORTS FOURTH QUARTER AND FULL YEAR 2023 FINANCIAL..
16/2/202416:47EDGAR2Form 4 - Statement of changes in beneficial ownership of..
16/2/202416:41EDGAR2Form 4 - Statement of changes in beneficial ownership of..
16/2/202416:39EDGAR2Form 4 - Statement of changes in beneficial ownership of..
13/2/202415:18EDGAR2Form 4 - Statement of changes in beneficial ownership of..
13/2/202415:15EDGAR2Form 4 - Statement of changes in beneficial ownership of..
13/2/202415:12EDGAR2Form 4 - Statement of changes in beneficial ownership of..
12/2/202405:19EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
08/2/202415:30PRNUSHalozyme To Report Fourth Quarter and Full Year 2023..
29/1/202415:15PRNUSHalozyme Announces Takeda Received European Commission..
23/1/202410:52EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
18/1/202415:07EDGAR2Form 4 - Statement of changes in beneficial ownership of..
18/1/202407:30PRNUSHalozyme Announces argenx Received Approval in Japan for..
17/1/202415:56EDGAR2Form 144 - Report of proposed sale of securities
17/1/202407:10EDGAR2Form 8-K - Current report
16/1/202415:26EDGAR2Form 144 - Report of proposed sale of securities
16/1/202407:15PRNUSHalozyme Announces Takeda Receives FDA Approval for HYQVIA®..
16/1/202400:15PRNUSHalozyme Announces Roche Receives European Commission..
12/1/202408:25PRNUSHalozyme to Host Investor Business Forum and Long-Term..
05/1/202415:04EDGAR2Form 4 - Statement of changes in beneficial ownership of..
13/12/202318:48EDGAR2Form 4 - Statement of changes in beneficial ownership of..
13/12/202315:40EDGAR2Form 144 - Report of proposed sale of securities
12/12/202315:21EDGAR2Form 144 - Report of proposed sale of securities
27/11/202307:00PRNUSHalozyme to Present at Upcoming Investor Conferences
16/11/202315:18EDGAR2Form 4 - Statement of changes in beneficial ownership of..
16/11/202308:00PRNUSHalozyme Announces argenx Receives European Commission..
15/11/202315:17EDGAR2Form 144 - Report of proposed sale of securities
14/11/202315:19EDGAR2Form 144 - Report of proposed sale of securities
06/11/202315:07EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
06/11/202315:04EDGAR2Form 8-K - Current report
06/11/202315:01PRNUSHALOZYME REPORTS THIRD QUARTER 2023 FINANCIAL AND OPERATING..
06/11/202306:30PRNUSHalozyme and Acumen Pharmaceuticals Enter Global..
30/10/202317:35PRNUSHalozyme To Report Third Quarter 2023 Financial and..
19/10/202306:15PRNUSPositive Topline Results Reported from Bristol Myers..

Su Consulta Reciente

Delayed Upgrade Clock